Your browser doesn't support javascript.
Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease.
Ricke-Hoch, Melanie; Stelling, Elisabeth; Lasswitz, Lisa; Gunesch, Antonia P; Kasten, Martina; Zapatero-Belinchón, Francisco J; Brogden, Graham; Gerold, Gisa; Pietschmann, Thomas; Montiel, Virginie; Balligand, Jean-Luc; Facciotti, Federica; Hirsch, Emilio; Gausepohl, Thomas; Elbahesh, Husni; Rimmelzwaan, Guus F; Höfer, Anne; Kühnel, Mark P; Jonigk, Danny; Eigendorf, Julian; Tegtbur, Uwe; Mink, Lena; Scherr, Michaela; Illig, Thomas; Schambach, Axel; Pfeffer, Tobias J; Hilfiker, Andres; Haverich, Axel; Hilfiker-Kleiner, Denise.
  • Ricke-Hoch M; Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
  • Stelling E; Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
  • Lasswitz L; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Gunesch AP; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Kasten M; German Center for Infection Research, Hanover-Braunschweig Site, Braunschweig, Germany.
  • Zapatero-Belinchón FJ; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hanover, Germany.
  • Brogden G; Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
  • Gerold G; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Pietschmann T; Department of Clinical Microbiology, Virology & Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden.
  • Montiel V; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Balligand JL; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Facciotti F; Department of Clinical Microbiology, Virology & Wallenberg Centre for Molecular Medicine (WCMM), Umeå University, Umeå, Sweden.
  • Hirsch E; Department of Biochemistry, University of Veterinary Medicine Hannover, Hanover Germany.
  • Gausepohl T; Institute of Experimental Virology, TWINCORE, Center for Experimental and Clinical Infection Research Hannover, Hanover, Germany.
  • Elbahesh H; German Center for Infection Research, Hanover-Braunschweig Site, Braunschweig, Germany.
  • Rimmelzwaan GF; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, and Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Höfer A; Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique, and Cliniques Universitaires Saint-Luc, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Kühnel MP; Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
  • Jonigk D; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.
  • Eigendorf J; Department of Cardiology and Angiology, Hannover Medical School, Hanover, Germany.
  • Tegtbur U; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine in Hannover (TiHo), Hannover, Germany.
  • Mink L; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine in Hannover (TiHo), Hannover, Germany.
  • Scherr M; Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research, Hanover, Germany.
  • Illig T; Institute for Pathology, Hannover Medical School, Hanover, Germany.
  • Schambach A; Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research, Hanover, Germany.
  • Pfeffer TJ; Institute for Pathology, Hannover Medical School, Hanover, Germany.
  • Hilfiker A; Biomedical Research in Endstage and Obstructive Lung Disease (BREATH), German Center for Lung Research, Hanover, Germany.
  • Haverich A; Institute for Pathology, Hannover Medical School, Hanover, Germany.
  • Hilfiker-Kleiner D; Institute of Sports Medicine, Hannover Medical School, Hanover, Germany.
PLoS One ; 16(8): e0255335, 2021.
Article in English | MEDLINE | ID: covidwho-1341502
ABSTRACT
The SARS-CoV-2 coronavirus has led to a pandemic with millions of people affected. The present study finds that risk-factors for severe COVID-19 disease courses, i.e. male sex, older age and sedentary life style are associated with higher prostaglandin E2 (PGE2) serum levels in blood samples from unaffected subjects. In COVID-19 patients, PGE2 blood levels are markedly elevated and correlate positively with disease severity. SARS-CoV-2 induces PGE2 generation and secretion in infected lung epithelial cells by upregulating cyclo-oxygenase (COX)-2 and reducing the PG-degrading enzyme 15-hydroxyprostaglandin-dehydrogenase. Also living human precision cut lung slices (PCLS) infected with SARS-CoV-2 display upregulated COX-2. Regular exercise in aged individuals lowers PGE2 serum levels, which leads to increased Paired-Box-Protein-Pax-5 (PAX5) expression, a master regulator of B-cell survival, proliferation and differentiation also towards long lived memory B-cells, in human pre-B-cell lines. Moreover, PGE2 levels in serum of COVID-19 patients lowers the expression of PAX5 in human pre-B-cell lines. The PGE2 inhibitor Taxifolin reduces SARS-CoV-2-induced PGE2 production. In conclusion, SARS-CoV-2, male sex, old age, and sedentary life style increase PGE2 levels, which may reduce the early anti-viral defense as well as the development of immunity promoting severe disease courses and multiple infections. Regular exercise and Taxifolin treatment may reduce these risks and prevent severe disease courses.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Dinoprostone / COVID-19 / Immunity Type of study: Observational study / Prognostic study Limits: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0255335

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Dinoprostone / COVID-19 / Immunity Type of study: Observational study / Prognostic study Limits: Adolescent / Adult / Animals / Female / Humans / Male / Middle aged / Young adult Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0255335